Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(lisdexamfetamine)
371 results
  • Recent advances in therapies for eating disorders. [Review]
    F1000Res 2019; 8Davis LE, Attia E
  • Eating disorders are serious psychiatric illnesses with high rates of morbidity and mortality. Effective treatments have traditionally included behaviorally focused therapies as well as several medication strategies. Recent years have seen promising developments in these treatments, including additional support for family-based approaches for children and adolescents, new evidence for "third-wave…
  • The effects of the prodrug Vyvanse on spatial working memory and adiposity in rats. [Journal Article]
    Pharmacol Biochem Behav 2019; 186:172765Ekstrand E, Murphy HM, Wideman CH
  • The present study investigated the influence of Vyvanse (lisdexamfetamine), a psychomotor stimulant, on spatial working memory, body weight, and adiposity in rats. Control and experimental rats were placed in individual cages equipped with a running wheel, and food and water were provided ad-libitum. The study was divided into three periods: 1) habituation, 2) experimental, and 3) withdrawal. Con…
  • Binge eating disorder revisited: what's new, what's different, what's next. [Journal Article]
    CNS Spectr 2019; 24(S1):4-13Citrome L
  • Binge eating disorder (BED) is the most common type of eating disorder. According to the most recent data available, the estimated lifetime prevalence of BED among US adults in the general population is 0.85% (men 0.42% and women 1.25%). Among psychiatric treatment populations, prevalence is several-fold higher. Although many people with BED are obese (BMI ≥ 30 kg/m2), roughly half are not. In th…
New Search Next